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ABSTRACT
Objectives To evaluate the impact of a screening strategy
in the first trimester, introduced in Denmark during 2004-
6, on the number of infants born with Down’s syndrome
and the number of chorionic villus samplings and
amniocenteses, and to determine detection and false
positive rates in the screened population in 2005 and
2006.
Design Population based cohort study.
Setting 19 Danish departments of gynaecology and
obstetrics and a central cytogenetic registry 2000-7.
Participants 65000 pregnancies per year.
MainoutcomemeasuresTheprimaryoutcomesmeasured
were number of fetuses and newborn infants with Down’s
syndrome diagnosed prenatally and postnatally and
number of chorionic villus samplings and amniocenteses
carried out. Secondary outcomes measured were number
of women screened in 2005 and 2006, screen positive
rate, and information on screening in 2005 and 2006 for
infants with a postnatal diagnosis of Down’s syndrome.
ResultsThenumberofinfantsbornwithDown’ssyndrome
decreased from 55-65 per year during 2000-4 to 31 in
2005and32in2006.Thetotalnumberofchorionicvillus
samplingsandamniocentesescarriedoutdecreasedfrom
7524 in 2000 to 3510 in 2006. The detection rate in the
screened population in 2005 was 86% (95% confidence
interval79%to92%)andin2006was93%(87%to97%).
Thecorrespondingfalsepositiverateswere3.9%(3.7%to
4.1%) and 3.3% (3.1% to 3.4%).
Conclusion The introduction of a combined risk
assessmentduringthe firsttrimesterata nationallevelin
Denmark halved the number of infants born with Down’s
syndrome.Thestrategyalso resultedin asharpdeclinein
the number of chorionic villus samplings and
amniocenteses carried out, even before full
implementation of the policy.
INTRODUCTION
In September 2004 the Danish National Board of
Health issued new guidelines for prenatal screening
and diagnosis.
1 These recommended that pregnant
womenshouldbeofferedinformationaboutscreening
methods in pregnancy and, if desired, a combined risk
assessment for Down’s syndrome in the first trimester
based on a combination of maternal age, nuchal
translucency scanning, and a biochemical test for
serum free β human chorionic gonadotrophin and
pregnancy associated plasma protein A, called the
double test. On the basis of this assessment women
were to be informed about their risk (given as odds,
such as 1:1250) of carrying a fetus with Down’s
syndrome. Women with a risk above a defined cut-off
(for example, 1:300) were to be offered an invasive
diagnostic procedure (chorionic villus sampling or
amniocentesis). According to the previous guidelines
from the Danish National Board of Health, pregnant
womenweretobeofferedchorionicvillussamplingor
amniocentesis if they were aged 35 or more, were at
increased risk of carrying a fetus with Down’s
syndrome on the basis of serum screening using a
triple test in the second trimester, or were at risk of an
inherited disease. In 2000 the uptake of invasive
diagnostic testing in women aged 35 or more was less
than50%,whereasaround20%ofallpregnantwomen
had nuchal translucency ultrasonography.
2 The triple
testwasnotofferedtoallwomenbutwasdoneinabout
10% of the population. Scans for malformations in the
second trimester were offered to 28% of women.
2
All 15 Danish counties decided to follow the
guidelines from 2004 and introduce combined risk
assessmentinthefirsttrimester.Thecostofintroducing
theprogramme(ultrasoundandlaboratoryequipment,
training, wages for new staff) was covered by the
counties and local hospitals. In 2004-6 the risk cut-off
for referral to invasive diagnostic procedures varied
betweencounties,from1:250to1:400.Thenewpolicy
was expected to detect 90% of fetuses with Down’s
syndrome at a 5% false positive rate on the basis of
calculations made on the Danish population in 2001.
We evaluated the impact at a national level of the
introduction of this new screening strategy on the
numberofinfantsbornwithDown’ssyndromeandon
the number of chorionic villus samplings and amnio-
centeses. We also assessed whether the detection and
false positive rates in the screened population for 2005
and 2006 were as expected.
METHODS
Denmark has a population of 5.4 million primarily
white people and about 65000 liveborn infants per
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BMJ | ONLINE FIRST | bmj.com page 1 of 7year (www.statistikbanken.dk). At birth everyone is
assignedauniquepersonalregistrationnumber,which
is used for identification in the Danish social and
healthcare system. This centralised, computer based,
registration system enables follow-up of individuals
through public registries.
From Statistics Denmark (www.statistikbanken.dk)
we retrieved data on the number of liveborn infants
born per year, the distribution of maternal age at
delivery,andthemeanmaternalageatdeliveryforthe
period 2000-6. Using the maternal age specific risk of
delivering an infant with Down’s syndrome we
calculated the expected number of liveborn infants
with Down’s syndrome.
3
In Denmark results from prenatal and postnatal
chromosome analyses are forwarded to the Danish
central cytogenetic registry. From there we obtained
information on the number of chorionic villus sam-
plings and amniocenteses carried out during 2000-6,
the indications for either procedure, and karyotypes.
In Denmark all newborn infants are examined by a
midwife. When an abnormality or malformation such
as Down’s syndrome is suspected, follow-up with a
paediatrician is initiated. The results of postnatal
chromosome analysis including the personal registra-
tion numbers of the mother and infant are sent to the
Danish central cytogenetic registry. The registry
provided information on the number of infants with
Down’s syndrome born during 2000-4 as well as the
personalregistrationnumberofallinfantswithDown’s
syndrome born during 2005-7 and their mothers.
For various political and practical reasons one
county (Funen) had not yet reported the results of
their chromosome analyses to the registry. We there-
foreobtainedinformationseparatelyonthenumberof
chorionic villus samplings and amniocenteses and
prenatal and postnatal cases of Down’s syndrome for
2000-6 from Funen’s chromosome laboratory.
Nuchaltranslucencyultrasonographyiscarriedoutby
nurses, midwives, and doctors certified by and in
accordance with the guidelines of the Fetal Medicine
Foundation in London (www.fetalmedicine.com/). All
obstetrics and gynaecology departments in Denmark
use the same fetal medicine software program (Astraia,
Germany)forcalculatingriskbasedonformulasderived
by the Fetal Medicine Foundation. In some hospitals
bloodsamplescollectedforthedoubletest(serumfree β
human chorionic gonadotrophin and pregnancy asso-
ciated plasma protein A) are analysed at local labora-
tories, whereas other hospitals send samples to a central
laboratory.MostofthelaboratoriesuseBrahmsKryptor
(Brahms,ImmunodiagnosticSystems,UK)forbiochem-
ical analyses and a few use an alternative immunoassay
(Delfia Xpress; PerkinElmer, Waltham, MA).
Evaluation of screening performance in 2005 and 2006
From the 19 obstetrics and gynaecology departments
we collected information on the number of women
whohadhadariskassessmentforDown’ssyndromein
the first trimester in 2005 and 2006, either as the
optimal combined test (maternal age, nuchal translu-
cency scan, and biochemistry) or by a combination of
maternal age and nuchal translucency scan or bio-
chemistry.To enableusto evaluatethe screenpositive
rate, the departments reported the number of women
given a risk assessment of 1:300 or more at the time of
screening.Wechosethisuniformcut-offtosimplifythe
presentationofdata,despitesomedepartmentsusinga
slightly different cut-off for referral to invasive
diagnostic testing.
In the calculation of screening performance we
included fetuses and newborn infants with Down’s
syndromewhenafirsttrimesterscreeningtesthadbeen
done in 2005 or 2006. Information about gestational
age at delivery for all infants with Down’s syndrome
born during 2005-7 was obtained from the Danish
National Board of Health.
We cross checked the personal registration numbers
o fw om enwhohadg ivenbirt ht oaninf antwit hDo wn’s
syndrome during 2005-7 with all Astraia database
servers in Denmark to obtain information on whether
screening had been carried out in the first trimester.
Informationaboutscreeningwasalsorequestedinthose
caseswhereDown’ssyndromewasdiagnosedprenatally
by an invasive procedure carried out for indications
other than an increased risk of Down’s syndrome.
RESULTS
A combined risk assessment in the first trimester was
introduced successively in Denmark. In January 2005
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Fig 1 | Number of liveborn infants and mean maternal age at delivery in Denmark, 2000-6
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Fig 2 | Number of fetuses and newborn infants with Down’s
syndrome diagnosed prenatally or postnatally in Denmark,
2000-6
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increasing to 13 counties (87%) by January 2006. By
June 2006 the whole of the country was covered.
The yearly number of deliveries in Denmark
decreased slightly during 2000-6 (fig 1), whereas the
mean maternal age at delivery increased from
29.7 years in 2000 to 30.3 years in 2006. Based on the
actual distribution of maternal age and if no prenatal
screening or invasive diagnosis had been carried out,
theestimatedexpectednumberofinfantswithDown’s
syndrome increased from 121 in 2000 to 132 in 2005
and 135 in 2006.
Number of newborn infants with Down’s syndrome
The number of newborn infants with Down’s syn-
dromedecreasedfrom55-65peryearin2000-4to31in
2005 and 32 in 2006. The total number of fetuses and
newborn infants with Down’s syndrome diagnosed
prenatallyorpostnatallyin2000-3wasstableataround
135-140 per year, with an increase to 157 in 2004, 161
in2005,and149in2006(fig2).Theproportionofcases
diagnosed prenatally increased from 53-61% during
2000-4, to 81% in 2005 and 79% in 2006.
Prenatal diagnostic procedure rate
The number of prenatal diagnostic procedures (chor-
ionic villus samplings or amniocenteses) decreased
from7524 in2000 to3510in 2006(fig 3). Thenumber
of chorionic villus samplings decreased from 3322 in
2000 to 2302 in 2006, while the number of amniocent-
eses carried out decreased from 4202 to 1208 in the
same years. This corresponds to an increase in the
proportion of chorionic villus samplings from 44% to
66%.
Screening performance in 2005 and 2006
About 65000 women were pregnant in Denmark
during 2005-6. In 2005 40815 women (62.8%) had a
risk assessment carried out in the first trimester,
increasing to 54830 (84.4%) in 2006. The remaining
womenhadnoriskassessmentdonebecausetheywere
offered an invasive diagnostic test for reasons other
thanascreenpositivetestresult,declinedscreening,or
failedtoreceiveanofferforreasonssuchasresidencyin
a county not yet offering screening. Figures 4 and 5
show the distribution of women eligible for screening
andthegroupsinwhichinfantswithDown’ssyndrome
were diagnosed prenatally and postnatally.
In 2005 a total of 1706 women (4.2%) had a risk of
1:300 or more (screen positive rate) and among these,
1388 women (81.4%) decided to have a diagnostic test
(fig 4). Seventy two per cent of the diagnostic
procedures done because of a screen positive risk
assessment were chorionic villus samplings, the
remainder were amniocenteses. In 2006 a total of
1899 women (3.5%) had a risk of 1:300 or more and
1704 (89.7%) underwent diagnostic testing as a
consequence of the screening result. Seventy six per
centofthediagnosticprocedurescarriedoutbecauseof
a screen positive risk assessment were chorionic villus
samplings.
Inthepopulationscreenedin2005thedetectionrate
of Down’s syndrome was 86% (95% confidence
interval 79% to 92%)—(101+3)/(101+3+16+1)—as
104 of 121 women carrying a fetus with Down’s
syndrome were screened true positive (fig 4). Thus 17
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Fig 3 | Number of amniocenteses and chorionic villus
samplings carried out in Denmark, 2000-6
Data on screening variables from 19 pregnancies in 2005 and 11 in 2006 resulting in newborn
infants with Down’ss y n d r o m ei nD e n m a r k
Year, maternal age*
(years)
Nuchal translucency
(mm)
Biochemistry
performed
Risk
assessment
2005:
25 1.3 Yes 1:23641
26 2.4 Yes 1:793
28 1.5 Yes 1:2838
28 1.5 Yes 1:2598
29 1.7 No 1:4954
29 1.8 Yes 1:2980
30 1.9 Yes 1:1831
30 1.8 Yes 1:195†
32 1.8 Yes 1:627
32 1.8 Yes 1:3193
34 2.3 Yes 1:682
35 Reported as “normal” No 1:1229
35 2.0 Yes 1:775
35 2.3 Yes 1:64†
36 1.9 Yes 1:3847
40 2.2 Yes 1:672
40 — Yes 1:3‡
41 2.0 Yes 1:466
46 2.0 Yes 1:729
2006:
24 1.6 Yes 1:1707
25 3.0 Yes 1:322
27 2.9 Yes 1:492
30 1.8 Yes 1:1764
31 1.7 Yes 1:79†
33 1.8 Yes 1:7693
34 1.5 Yes 1:3246
35 3.0 Yes 1:66†
37 6.3 Yes 1:5†
37 2.3 No (twins) 1:206†
40 2.3 Yes 1:79†
*Maternal age at time of nuchal translucency scan. If no scan was done then maternal age at week 12+4 is
reported.
†Offered diagnostic testing.
‡Gestational age at screening 14+2, offered diagnostic testing.
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ofthesewomenhadanamniocentesisonsuspicionofa
malformation after the 18-20 week scan, and the
pregnancy was terminated (fig 4). An adjusted detec-
tionratetakingintoaccountfetallossfromscreeningto
time of birth (estimated as 25%
4) was 82% (95%
confidenceinterval73%to90%).Thefalsepositiverate
was 3.9% (3.7% to 4.1%).
In 2006 the detection rate was 93% (87% to 97%)—
(92+5)/(92+5+6+1)—asonlysevenwomenreceiveda
false negative screening result. One of these women
had an amniocentesis on suspicion of a malformation,
andthepregnancywasterminated(fig5).Theadjusted
detection rate taking fetal loss into account was
estimated at 92% (83% to 97%). The false positive
rate was 3.3% (3.1% to 3.4%).
The odds of being affected (carrying a fetus with
Down’s syndrome) after receiving a screen positive
risk assessment during the first trimester were 1:16 in
2005and1:20in2006.Theoddsofbeingaffectedafter
receiving a screen negative result were 1:2301 in 2005
and 1:7562 in 2006.
The odds of being affected after undergoing chor-
ionic villus sampling or amniocentesis owing to
advanced maternal age were similar in 2005 and
2006 (1:65 and 1:75); 15 fetuses with Down’s
syndrome were diagnosed among 980 women in
2005 and eight fetuses among 600 women in 2006.
Indications other than advanced maternal age or high
risk after screening for undergoing chorionic villus
sampling or amniocentesis were mainly family history
of chromosomal abnormality, mental retardation or
monogenicinheriteddisease,orahighriskonthebasis
of serum screened in the second trimester.
Thirty infants with Down’s syndrome were born to
motherswhohadhadariskassessmentdoneinthefirst
trimester during 2005 and 2006. The table gives the
details of the risk assessments.
DISCUSSION
Even before full implementation of the policy for
combined risk assessment during the first trimester in
Denmark, the number of infants born with Down’s
syndrome decreased by about 50% and the number of
cases diagnosed prenatally increased by around 30%.
The number of fetuses and newborn infants with
Down’ssyndromediagnosedprenatallyorpostnatally
increased in the period 2000-5, with a slight decline in
2006(fig2).Thiswaspartlyduetoincreasingmaternal
age, but was as expected because more fetuses with
Down’s syndrome are lost spontaneously than those
that are chromosally normal. This increased rate has
been estimated at around 25% from week 14 to term.
4
Based on the known distribution of maternal age at
delivery in 2005 and 2006, 132 and 135 infants with
Down’s syndrome would have been expected in our
populationof65000liveborninfantsifthemothershad
no prenatal intervention. Down’ss y n d r o m ew a s
diagnosed in 31 infants postnatally and 130 prenatally
in2005andin32infantspostnatallyand117prenatally
in 2006. Given a rate for fetal loss of 25%, this
corresponds to 129 infants with Down’s syndrome
diagnosed postnatally in 2005 and 120 diagnosed
postnatally in 2006. In 2005 the expected numbers
Estimated number of pregnancies eligible 
for screening in first trimester
2005 (approximately 65 000)
First trimester risk 
assessment
(n=40 815)
Screen positive
risk ≥1:300
(n=1706)
Screen negative
risk < 1:300
(n=39 109)
Invasive 
procedure
(n=1388)
Invasive 
procedure due 
to advanced
maternal age
(n=980)
Invasive 
procedure on
other indications
(n=1294)
Invasive 
procedure
(n=2274)
No invasive 
procedure
(n=318)
No invasive 
procedure
(approximately 22 000)
Down’s
syndrome
diagnosed
prenatally
(n=101)
Down’s
syndrome
diagnosed
postnatally
(n=3)
Down’s
syndrome
diagnosed
postnatally
(n=16)
Down’s
syndrome
diagnosed
prenatally
(n=1)
Down’s
syndrome
diagnosed
prenatally
(n=15)
Down’s
syndrome
diagnosed
prenatally
(n=13)
Down’s
syndrome
diagnosed
postnatally
(n=17)
No first trimester screening
(approximately 24 000)
Fig 4 | Number of fetuses and newborn infants with Down’s syndrome diagnosed prenatally or postnatally according to screening
results in Denmark, 2005. Invasive procedures are chorionic villus samplings or amniocenteses
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reported number was lower than expected. This may
beduetochancefluctuation,aswebelievefollow-upis
complete.Thefollow-uptimeforthenumbersreported
from 2006 is, however, relatively short and a few cases
may therefore still be reported.
In 2005 national screening was not fully implemen-
ted. One third of the women were either not offered
screening or declined. These women gave birth to a
total of 17 infants with Down’s syndrome. In 2006 the
proportionof non-screenedwomen decreasedto 15%,
asscreeningwasthenavailableformostwomen.About
8500 women who were not offered screening or
declined screening or a diagnostic test in 2006 gave
birth to a total of 11 infants with Down’s syndrome.
The national guidelines on prenatal screening empha-
sise that risk assessment for Down’s syndrome should
bedoneonlyifwomenchoosethetestonthebasisofan
informed choice. Therefore despite the programme
now being accessible to all pregnant women in
Denmark, it is expected that a proportion will still
choose not to be screened. The size of this proportion
when screening is fully available remains to be
established; however, in 2005 only 2% of the popula-
tion in two counties declined screening.
5 Studies on
Danish women’sattitude,knowledgeaboutscreening,
and choice of test are ongoing.
6
We found that the number of prenatal diagnostic
tests (chorionic villus samplings and amniocenteses)
carriedoutyearly decreasedbymore than50%during
2000-6. A decrease in the number of prenatal
diagnostic procedures could be seen even before the
policy was changed, probably because pregnant
women became aware of alternative prenatal investi-
gations such as nuchal translucency scanning (fig 3).
ThiswascertainlythecaseinandaroundCopenhagen,
whenaprospectivestudyofaround10000womenwas
done in 1998-2001.
7 Nuchal translucency scanning
was introduced in some departments even before the
national guidelines were changed.
In 2005 and 2006 about 3% of women still had an
invasive diagnostic procedure done because of indica-
tions other than a screen positive test result, with a
tendencytowardsareducednumberoftestsfrom2005
to 2006 (2274 women in 2005, 1805 in 2006). The
decrease was mainly due to fewer women choosing
invasive diagnostic tests on the basis of advanced
maternal age, as 980 invasive procedures were carried
out for that indication in 2005 but decreased to 600 in
2006. The relatively high number of women choosing
chorionic villus sampling or amniocentesis was prob-
ably partly due to lack of implementation of the new
screening programme. It is also possible that women
who had a diagnostic procedure for a previous
pregnancy because they were aged 35 or more may
have requested a diagnostic test again. When the new
screening strategy based on ultrasound and biochem-
istry has been available for some years we expect the
number of invasive diagnostic tests done because of
advanced maternal age to decrease even further.
We found that 10-20% of women with a screen
positive test result did not undergo an invasive
diagnostic test. This is in accordance with reports
from the Copenhagen First Trimester Study.
7 For
Estimated number of pregnancies eligible 
for screening in first trimester
2006 (approximately 65 000)
First trimester risk 
assessment
(n=54 830)
Screen positive
risk ≥ 1:300
(n=1899)
Screen negative
risk < 1:300
(n=52 931)
Invasive 
procedure
(n=1704)
Invasive 
procedure due 
to advanced
maternal age
(n=600)
Invasive 
procedure on
other indications
(n=1205)
Invasive 
procedure
(n=1805)
No invasive 
procedure
(n=195)
No invasive 
procedure
(approximately 8500)
Down’s
syndrome
diagnosed
prenatally
(n=92)
Down’s
syndrome
diagnosed
postnatally
(n=5)
Down’s
syndrome
diagnosed
postnatally
(n=6)
Down’s
syndrome
diagnosed
prenatally
(n=1)
Down’s
syndrome
diagnosed
prenatally
(n=8)
Down’s
syndrome
diagnosed
prenatally
(n=16)
Down’s
syndrome
diagnosed
postnatally
(n=11)
No first trimester screening
(approximately 10 500)
Fig 5 | Number of fetuses and newborn infants with Down’s syndrome diagnosed prenatally or postnatally according to screening
results in Denmark, 2006. Invasive procedures are chorionic villus samplings or amniocenteses
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by assisted reproduction technologies, or risk near the
cut-off) some women do not want an invasive
diagnostic test, probably because of the associated
risk of miscarriage.
The difference in odds of carrying a fetus with
Down’ssyndromeforthosewhoweretestedbecauseof
a screen positive risk assessment (1:16 in 2005, 1:20 in
2006) compared with that of being tested because of
advanced maternal age (1:65 in 2005, 1:75 in 2006)
clearly illustrates the rationale in screening using a
combined risk assessment in the first trimester. As
expected, this strategy reduces the number of unne-
cessary diagnostic procedures. The procedure related
risk of miscarriage after chorionic villus sampling or
amniocentesis is reported to be 1%.
8 In the group of
women having an invasive diagnostic test done
because of advanced maternal age in 2005 and 2006
16 chromosomally normal fetuses would then have
been miscarried to diagnose 23 cases of Down’s
syndrome. This should be compared with the 31
fetuses possibly miscarried to diagnose 193 cases of
Down’ssyndromeinthegroupofwomenwithascreen
positive test result. Combined risk assessment in the
first trimester is not only a more effective screening
methodthanmaternalagealone,italsoreducestherisk
of miscarrying chromosomally normal fetuses when
used as reason to be referred for testing instead of
maternal age. Thus the false positive rate of prenatal
diagnostictestinghasbeenmuchreducedbychanging
the selection criterion from maternal age to risk
assessment in the first trimester. The false negative
rate has also changed: previously those women who
chose to have chorionic villus sampling or amniocent-
esisbecauseofadvancedmaternalagehadadiagnostic
test.Currentlywomenchoosetohavea screeningtest;
0.4 women per 1000 in 2005 and 0.1 per 1000 in 2006
subsequentlydeliveredachildwithDown’ssyndrome,
despite having a risk assessment below the 1:300 cut-
off. These few women may feel more resentment
towards the system that failed them than those women
who chose not to have an invasive diagnostic test
becauseofadvancedmaternalage.Thisemphasisesthe
importance of informing all women about the limita-
tions of screening.
For false positive rates of 3.9% and 3.3% in the
screened populations we found detection rates for
Down’s syndrome of 86% in 2005 and 93% in 2006.
This is in accordance with the screening performance
expectedbytheDanishNationalBoardofHealthwhen
it decided to implement this new screening strategy.
This performance may be considered high, especially
as the programme in 2005 and 2006 in many centres
used a completely new screening method. Further-
more, we report the result of routine clinical practice,
wherenotallriskassessmentsarebasedontheoptimal
variables (combination of maternal age, nuchal trans-
lucencyscan,andbiochemistry)assomearegivenonly
on maternal age and nuchal translucency scan or
biochemistry.Otherauthorshavealsoreportedscreen-
ing resultsachieved in routineclinicalpractice in upto
13 centres, with detection rates between 83% and 93%
andfalsepositiveratesbetween3.9%and5.9%.
9-13One
studycollecteddatafrom44centresintheNetherlands
and found a detection rate of 71% for a false positive
rate of 4.7%.
14 The authors explain the relatively low
detection rate by too small measurements used for
nuchal translucency, and expect to improve the
detection rate by establishing quality assurance on
the measurements. In a large prospective multicentre
study the detection rate using a combined screening
programme in the first trimester was 92.6% for a false
positiverateof5.2%.
15Ourdatashowthatitispossible
to introduce this screening strategy in as many as 19
differentcentresandstillobtainnationaldetectionand
false positive rates similar to those from specialised
centres.
It is well known that implementation of new screen-
ing strategies requires effort, and many countries are
currentlyfacingvariousproblemsintryingtoachievea
national strategy.
16-18 In Denmark, with its public, free
of charge hospital system, we have succeeded in
establishing a strong national organisation for fetal
medicine.Recruitmentandtrainingofsonographersas
well as quality control are in accordance with the
guidelines from the Fetal Medicine Foundation in
London (www.fetalmedicine.com). We have imple-
mented national guidelines on screening in the first
trimester,andfrom1January2007acommoncut-offof
1:300 for referral to invasive diagnostic testing at the
time of screening. Furthermore, the use of the same
database software in all departments allows national
datatobemerged.Anationalqualitydatabasehasbeen
established that merges data from all fetal medicine
units,the Danishnationalcytogeneticregistry,andthe
nationalpatientregistry.Thiswillallowfollow-upofall
screened women at a national level, as well as
monitoring of detection rates, false positive rates, and
invasive testing rates, a quality control that is con-
sidered essential after the implementation of a new
screening programme.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Many countries are currently trying to achieve national screening strategies for Down’s
syndrome
Nonehasdescribedhowacombinedscreeningstrategyinthefirsttrimesteraffectsnumbersof
infants born with Down’ss y n d r o m eo rr a t eo fi n v a s i v ep r o c e d u r e s
Detectionrates and false positiverates for the combined first trimesterriskassessmenthave
been reported only from specialised centres or from regional experience
WHAT THIS STUDY ADDS
After implementation of a national screening policy in Denmark, the number of infants born
with Down’s syndrome and the rate of invasive procedures was noticeably reduced
The screening strategy achieved high detection rates and low false positive rates
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